TABLE 2.
Epidemiological data and resistance phenotypes of all P. aeruginosa isolates with reduced susceptibility to imipenem and resistance to ceftazidime
| Isolate | Specimen | Date of recovery | Warda | MBL enzymeb | MIC (μg/ml)c |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIP | TZP | CAZ | FEP | ATM | IMP | MEM | COL | AMK | GEN | TOB | CIP | |||||
| MBL-producing isolates | ||||||||||||||||
| PA399 | Urine | November 2007 | Urology | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 1 | 8 | ≥16 | ≥16 | ≥4 |
| PA462 | Ascitic fluid | June 2008 | General surgery | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 1 | 4 | ≥16 | ≥16 | ≥4 |
| PA465 | Drainage | July 2008 | General surgery | VIM-2 | ≥128 | 64 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 2 | 8 | ≥16 | ≤1 | ≥4 |
| PA469 | Wound | August 2008 | General surgery | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 1 | 8 | ≥16 | ≥16 | ≥4 |
| PA475 | Wound | September 2008 | General surgery | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 1 | 4 | ≥16 | ≥16 | ≥4 |
| PA477 | Drainage | September 2008 | General surgery | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 1 | 8 | ≥16 | ≥16 | ≥4 |
| PA481 | Urine | October 2008 | Urology | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | 16 | ≥16 | ≥16 | 1 | 8 | ≥16 | ≥16 | ≥4 |
| PA500 | Tracheal secretion | February 2009 | Surgical ICU | VIM-1 | ≥128 | ≥128 | ≥64 | ≥64 | 4 | ≥16 | ≥16 | 1 | ≤2 | ≥16 | 8 | ≥4 |
| PA510 | Tracheal secretion | May 2009 | Medical ICU | VIM-2 | ≥128 | ≥128 | ≥64 | ≥64 | ≥64 | ≥16 | ≥16 | 1 | 4 | ≥16 | ≥16 | ≥4 |
| MBL-negative isolates | ||||||||||||||||
| PA459 | Tracheal secretion | June 2008 | Surgical ICU | − | ≥128 | ≥128 | 32 | 8 | 16 | ≥16 | 8 | 1 | 2 | 1 | 1 | 0.25 |
| PA460 | Wound | June 2008 | General surgery | − | ≥128 | ≥128 | 32 | 16 | 16 | ≥16 | 8 | 1 | 4 | ≥16 | ≥16 | ≥4 |
| PA479 | Urine | October 2008 | General surgery | − | ≥128 | ≥128 | ≥64 | ≥64 | 32 | 8 | ≥16 | 1 | 8 | ≥16 | ≥16 | ≥4 |
| PA483 | Wound | October 2008 | Surgical ICU | − | ≥128 | ≥128 | ≥64 | 32 | 64 | ≥16 | ≥16 | 1 | 2 | 1 | 1 | 0.25 |
| PA494 | Urine | December 2008 | Neurosurgery | − | ≥128 | ≥128 | 32 | 8 | 16 | ≥16 | 8 | 1 | 8 | 8 | 1 | ≥4 |
| PA507 | Drainage | April 2009 | Surgical ICU | − | ≥128 | ≥128 | 32 | 16 | 16 | ≥16 | 4 | 1 | 16 | ≥16 | 1 | 0.25 |
| PA509 | Wound | May 2009 | Internal medicine | − | ≥128 | ≥128 | 32 | 16 | 8 | ≥16 | ≥16 | 2 | 64 | ≥16 | ≥16 | ≥4 |
ICU, intensive care unit.
The type of MBL enzyme is given for the isolates that produce MBL. Some isolates did not produce MBL (−).
Abbreviations for antimicrobial agents: PIP, piperacillin; TZP, piperacillin-tazobactam; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IMP, imipenem; MEM, meropenem; COL, colistin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin.